Merck suspends Zilmax sales amid cattle mobility concerns

Merck (MRK -0.8%temporarily suspends sales of the beta-agonist Zilmax in the U.S.

The move comes on the heels of Tyson's (TSN -0.1%) decision to discontinue purchases of cattle which have been fed the supplement.

MRK has laid out a five-step plan to address allegations and suggestions that ZIlmax may be causing cattle to have difficulty walking.

Sales of Zilmax were $159M last year.

Eli Lilly (LLY -0.9%) markets a less potent beta-agonist called Optaflexx.

From other sites
Comments (1)
  • warrenrial
    , contributor
    Comments (550) | Send Message
    Tyson made the right decision.
    16 Aug 2013, 01:50 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs